CY1109119T1 - Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη - Google Patents
Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινηInfo
- Publication number
- CY1109119T1 CY1109119T1 CY20091100580T CY091100580T CY1109119T1 CY 1109119 T1 CY1109119 T1 CY 1109119T1 CY 20091100580 T CY20091100580 T CY 20091100580T CY 091100580 T CY091100580 T CY 091100580T CY 1109119 T1 CY1109119 T1 CY 1109119T1
- Authority
- CY
- Cyprus
- Prior art keywords
- lamotrigin
- long
- pharmaceutical forms
- term release
- release including
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0217492A GB0217492D0 (en) | 2002-07-29 | 2002-07-29 | Novel method of treatment |
GB0217493A GB0217493D0 (en) | 2002-07-29 | 2002-07-29 | Novel methods of treatment |
GB0313801A GB0313801D0 (en) | 2003-06-13 | 2003-06-13 | Novel methods of treatment |
EP03766343A EP1524981B1 (fr) | 2002-07-29 | 2003-07-28 | Formulations a liberation prolongee contenant de la lamotrigine |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109119T1 true CY1109119T1 (el) | 2014-07-02 |
Family
ID=31499035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100580T CY1109119T1 (el) | 2002-07-29 | 2009-05-29 | Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη |
Country Status (29)
Country | Link |
---|---|
US (1) | US20050032799A1 (fr) |
EP (1) | EP1524981B1 (fr) |
JP (2) | JP4744142B2 (fr) |
KR (1) | KR100882707B1 (fr) |
CN (1) | CN100363007C (fr) |
AR (1) | AR040709A1 (fr) |
AT (1) | ATE424827T1 (fr) |
AU (1) | AU2003260336C1 (fr) |
BR (1) | BRPI0313148B8 (fr) |
CA (1) | CA2493301A1 (fr) |
CO (1) | CO5680405A2 (fr) |
CY (1) | CY1109119T1 (fr) |
DE (1) | DE60326590D1 (fr) |
DK (1) | DK1524981T3 (fr) |
ES (1) | ES2323268T3 (fr) |
HK (1) | HK1077003A1 (fr) |
IL (1) | IL166424A (fr) |
IS (1) | IS2681B (fr) |
MA (1) | MA27509A1 (fr) |
MX (1) | MXPA05001243A (fr) |
MY (1) | MY141049A (fr) |
NO (1) | NO334221B1 (fr) |
NZ (1) | NZ537885A (fr) |
PL (1) | PL213565B1 (fr) |
PT (1) | PT1524981E (fr) |
RU (1) | RU2325163C2 (fr) |
SI (1) | SI1524981T1 (fr) |
TW (1) | TWI342213B (fr) |
WO (1) | WO2004012741A1 (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7939102B2 (en) * | 2002-06-07 | 2011-05-10 | Torrent Pharmaceuticals Ltd. | Controlled release formulation of lamotrigine |
CA2493301A1 (fr) * | 2002-07-29 | 2004-02-12 | Glaxo Group Limited | Formulations a liberation prolongee contenant de la lamotrigine |
WO2005051325A2 (fr) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Base libre de carvedilol, ses sels, formes anhydres ou solvats, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et methodes de traitement ou d'administration |
US20060039975A1 (en) * | 2004-08-20 | 2006-02-23 | Zalman Vilkov | Paroxetine formulations |
CA2604052C (fr) * | 2005-04-06 | 2014-07-08 | Adamas Pharmaceuticals, Inc. | Methode et compositions de traitement des affections du snc |
WO2008109343A1 (fr) * | 2007-03-01 | 2008-09-12 | Memory Pharmaceuticals Corporation | Procédés de traitement des troubles bipolaires et des déficiences de la mémoire et/ou cognitives associées avec ceux-ci avec du (+)-4-(2-chloro-3-cyanophényl)-1,4-dihydro-2,6-diméthylpyridine-3,5-dicarboxylate d'isopropyle et de 2-méthoxyéthyle |
US20090022789A1 (en) * | 2007-07-18 | 2009-01-22 | Supernus Pharmaceuticals, Inc. | Enhanced formulations of lamotrigine |
US8486927B2 (en) * | 2007-11-09 | 2013-07-16 | Thar Pharmaceuticals | Crystalline forms of lamotrigine |
US20090196924A1 (en) * | 2008-02-04 | 2009-08-06 | Pramod Kharwade | Controlled-release lamotrigine formulations |
US20100323016A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
US20100323015A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
US20100120906A1 (en) * | 2008-07-18 | 2010-05-13 | Valeant Pharmaceuticals International | Modified release formulation and methods of use |
MX365650B (es) | 2009-12-02 | 2019-06-10 | Adamas Pharmaceuticals Inc | Composiciones de amantadina y metodos para su uso. |
WO2011086568A1 (fr) * | 2010-01-13 | 2011-07-21 | Accutest Research Laboratories (I) Pvt. Ltd | Composition à libération contrôlée pour la lamotrigine |
KR20140016260A (ko) * | 2011-02-03 | 2014-02-07 | 루핀 리미티드 | 베포타스틴의 경구용 방출 조절 약제 조성물 |
WO2014159275A1 (fr) * | 2013-03-14 | 2014-10-02 | PharmTak, Inc. | Compositions pharmaceutiques à libération contrôlée comprenant de la lamotrigine et procédés de production de celles-ci |
CN103920134A (zh) * | 2014-05-08 | 2014-07-16 | 崔韡 | 一种治疗儿童眩晕的缓释片及其制备方法 |
RU2624229C2 (ru) * | 2015-12-21 | 2017-07-03 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Таблетки клозапина с замедленным высвобождением и способ их получения |
RU2613192C1 (ru) * | 2016-02-18 | 2017-03-15 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Таблетки клозапина с пролонгированным высвобождением |
BR112019016118A2 (pt) * | 2017-02-03 | 2020-07-14 | Jubilant Generics Limited | forma farmacêutica de dosagem de suspensão oral de lamotrigina |
BR112020003375A2 (pt) | 2017-08-24 | 2020-08-25 | Adamas Pharma, Llc | composições de amantadina, preparações das mesmas, e métodos de uso |
WO2019080077A1 (fr) * | 2017-10-27 | 2019-05-02 | 长庚医疗财团法人林口长庚纪念医院 | Procédé d'évaluation du risque de réactions cutanées défavorables à un médicament provoquées par la lamotrigine médicament antiépileptique, son réactif de détection et son utilisation |
US10213394B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
US10213393B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság | Composition and method for treating neurological disease |
US20190247331A1 (en) | 2018-02-15 | 2019-08-15 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
CN113214177B (zh) * | 2021-04-16 | 2022-05-03 | 上海奥科达生物医药科技有限公司 | 一种拉莫三嗪水合物的晶体形式、其制备方法及包含其的组合物 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704295A (en) * | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
US4556552A (en) * | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
JPH0667828B2 (ja) * | 1985-10-09 | 1994-08-31 | 日研化学株式会社 | バルプロ酸ナトリウムの持続性顆粒製剤 |
US4775536A (en) * | 1986-02-24 | 1988-10-04 | Bristol-Myers Company | Enteric coated tablet and process for making |
US4816262A (en) * | 1986-08-28 | 1989-03-28 | Universite De Montreal | Controlled release tablet |
GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
DE69207863T2 (de) * | 1991-11-13 | 1996-06-05 | Glaxo Canada | Vorrichtung zur kontrollierten Wirkstoffreigabe |
US5733575A (en) * | 1994-10-07 | 1998-03-31 | Bpsi Holdings, Inc. | Enteric film coating compositions, method of coating therewith, and coated forms |
AUPN605795A0 (en) * | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
CA2264182A1 (fr) * | 1996-08-23 | 1998-02-26 | Algos Pharmaceutical Corporation | Anticonvulsivant renfermant une composition pour traiter la douleur neurogene |
GB9625795D0 (en) * | 1996-12-12 | 1997-01-29 | Smithkline Beecham Plc | Novel treatment |
US6046716A (en) * | 1996-12-19 | 2000-04-04 | Colorado Microdisplay, Inc. | Display system having electrode modulation to alter a state of an electro-optic layer |
CA2216215A1 (fr) * | 1997-04-05 | 1998-10-05 | Isa Odidi | Formulations a liberation prolongee, utilisant des polymeres intelligents, avec caracteristiques de mouillabilite opposees, correspondant a une hydrophobie et a une hydrophilie |
GB9726987D0 (en) * | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
AU1238500A (en) * | 1998-11-02 | 2000-05-22 | Alza Corporation | Controlled delivery of active agents |
GB9930079D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
GB0024517D0 (en) * | 2000-10-06 | 2000-11-22 | Glaxo Group Ltd | Use of medicaments |
DE10224170A1 (de) * | 2002-05-31 | 2003-12-11 | Desitin Arzneimittel Gmbh | Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung |
CA2493301A1 (fr) * | 2002-07-29 | 2004-02-12 | Glaxo Group Limited | Formulations a liberation prolongee contenant de la lamotrigine |
-
2003
- 2003-07-28 CA CA002493301A patent/CA2493301A1/fr not_active Withdrawn
- 2003-07-28 PT PT03766343T patent/PT1524981E/pt unknown
- 2003-07-28 PL PL374982A patent/PL213565B1/pl unknown
- 2003-07-28 BR BRPI0313148A patent/BRPI0313148B8/pt not_active IP Right Cessation
- 2003-07-28 DK DK03766343T patent/DK1524981T3/da active
- 2003-07-28 NZ NZ537885A patent/NZ537885A/en not_active IP Right Cessation
- 2003-07-28 WO PCT/EP2003/008368 patent/WO2004012741A1/fr active IP Right Grant
- 2003-07-28 AR AR20030102702A patent/AR040709A1/es not_active Application Discontinuation
- 2003-07-28 AT AT03766343T patent/ATE424827T1/de active
- 2003-07-28 EP EP03766343A patent/EP1524981B1/fr not_active Expired - Lifetime
- 2003-07-28 DE DE60326590T patent/DE60326590D1/de not_active Expired - Lifetime
- 2003-07-28 SI SI200331585T patent/SI1524981T1/sl unknown
- 2003-07-28 AU AU2003260336A patent/AU2003260336C1/en not_active Expired
- 2003-07-28 JP JP2004525362A patent/JP4744142B2/ja not_active Expired - Lifetime
- 2003-07-28 MY MYPI20032831A patent/MY141049A/en unknown
- 2003-07-28 ES ES03766343T patent/ES2323268T3/es not_active Expired - Lifetime
- 2003-07-28 RU RU2005105353/14A patent/RU2325163C2/ru active
- 2003-07-28 KR KR1020057001633A patent/KR100882707B1/ko active IP Right Grant
- 2003-07-28 TW TW092120477A patent/TWI342213B/zh not_active IP Right Cessation
- 2003-07-28 MX MXPA05001243A patent/MXPA05001243A/es active IP Right Grant
- 2003-07-28 CN CNB038223716A patent/CN100363007C/zh not_active Expired - Lifetime
- 2003-07-29 US US10/629,177 patent/US20050032799A1/en not_active Abandoned
-
2005
- 2005-01-20 IL IL166424A patent/IL166424A/en unknown
- 2005-01-28 MA MA28074A patent/MA27509A1/fr unknown
- 2005-01-28 CO CO05007005A patent/CO5680405A2/es not_active Application Discontinuation
- 2005-02-22 NO NO20050948A patent/NO334221B1/no not_active IP Right Cessation
- 2005-02-23 IS IS7707A patent/IS2681B/is unknown
- 2005-09-22 HK HK05108373.5A patent/HK1077003A1/xx not_active IP Right Cessation
-
2009
- 2009-05-29 CY CY20091100580T patent/CY1109119T1/el unknown
-
2010
- 2010-10-15 JP JP2010232745A patent/JP2011057683A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109119T1 (el) | Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη | |
CY1116693T1 (el) | Συνδυασμος αζελαστινης και κυκλεσονιδης | |
IS7431A (is) | Samrunaefnasambönd lyfja eða frumudrepandi efna og líffræðilega virkra peptíða | |
CY1108874T1 (el) | ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ | |
CY1107176T1 (el) | Συνθεσεις και μεθοδος για θεραπεια μολυνσης σε βοοειδη και χοιρους | |
ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
IS7076A (is) | Bólusetning með einföldum skammti af Mycoplasma hyopneumoniae, og notkun efnisins í lækningaskyni | |
LU92517I2 (fr) | Delamanide et ses dérivés pharmaceutiquement acceptables | |
DK1288205T3 (da) | Nye phenylalanin-derivater | |
LU92513I2 (fr) | Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi) | |
CY1111613T1 (el) | Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv | |
ECSP034773A (es) | Pirazolopirimmidinas como agentes terapeuticos | |
NO20076613L (no) | Farmasoytiske formuleringer og anvendelse derav | |
CY1108748T1 (el) | Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων | |
AR034213A1 (es) | Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv | |
DE60336664D1 (de) | Nichtnukleosidische reverse-transkriptase-hemmer | |
CY1109880T1 (el) | ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR | |
AR031152A1 (es) | Tratamientos nuevos para el sindrome de piernas inquietas | |
CY1107605T1 (el) | Θεραπευτικη αγωγη | |
CY1114133T1 (el) | ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ | |
SE0101932D0 (sv) | Pharmaceutical combinations | |
CY1110712T1 (el) | Χρηση ν-(3-μεθοξυ-5-μεθυλπυραζιν-2-υλ)-2-(4-[1,3,4-οξαδιαζολ-2-υλ]φαινυλ)πυριδινο-3-σουλφοναμιδης στη θεραπευτικη αντιμετωπιση του καρκινου | |
DK1513836T3 (da) | Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf | |
CY1109001T1 (el) | Οι καππα-οπιοιδεις αγωνιστες στη θεραπεια των παθησεων της κυστης | |
DK1556382T3 (da) | 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf |